Ivermectin Substipharm

Ivermectin, the active ingredient in Ivermectin Substipharm, is an Avermectin (antiparasitic) presented as an oral formulation for oral use. It treats a range of parasitic infections such as onchocerciasis, strongyloidiasis, scabies and lice infestations in humans. The product complies with European Union pharmaceutical standards and is manufactured under GMP conditions. It is intended for prescription use by qualified healthcare professionals. The formulation is suitable for adult patients and is available for bulk distribution.

GNH USA supplies Ivermectin Substipharm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectin is an antiparasitic agent that acts on a variety of helminth and ectoparasite infections. - Onchocerciasis (river blindness): eliminates microfilariae, reducing skin and ocular lesions. - Strongyloidiasis: eradicates intestinal larvae, preventing chronic infection. - Scabies: kills Sarcoptes mites, relieving itching and skin lesions. - Lice infestations: destroys head and body lice, halting transmission. - Other helminth infections: provides broad-spectrum activity against several nematodes.

Ivermectin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, usually self‑limiting. - Abdominal pain: cramping or discomfort. - Pruritus: mild itching at the site of parasite death. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Neurologic events: seizures, ataxia, or altered consciousness. - Hypotension: sudden drop in blood